Objective-Liver X receptors (LXRα, LXRβ) are master regulators of cholesterol homeostasis. In the endothelium, perturbations of cell cholesterol have an impact on fundamental processes. We, therefore, assessed the effects of LXR activation on endothelial functions related to angiogenesis in vitro and in vivo. Methods and Results-LXR agonists (T0901317, GW3965) blunted migration, tubulogenesis, and proliferation of human umbilical vein endothelial cells. By affecting endothelial cholesterol homeostasis, LXR activation impaired the compartmentation of vascular endothelial growth factor receptor-2 in lipid rafts/caveolae and led to defective phosphorylation and downstream signaling of vascular endothelial growth factor receptor-2 upon vascular endothelial growth factor-A stimulation. Consistently, the antiangiogenic actions of LXR agonists could be prevented by coadministration of exogenous cholesterol. LXR agonists reduced endothelial sprouting from wild-type but not from LXRα 
L iver X receptors α and β (LXRα/NR1H3, LXRβ/NR1H2) are retinoid X receptor α (RXRα/NR2B1) heterodimers belonging to the nuclear hormone receptor superfamily. Through coordinate transcriptional actions, LXRs orchestrate cellular and systemic cholesterol homeostasis. 1 LXRs reduce cholesterol absorption, inhibit cholesterol synthesis, and favor cholesterol output via reverse transport and bile secretion. Endogenous LXR agonists, such as 22(R)-, 24-, and 25-hydroxycholesterol, are formed upon cholesterol loading of cells and mediate this physiological feedback loop. 2 Furthermore, LXR activation with synthetic agonists (eg, T0901317, GW3965) exerts beneficial effects in atherosclerosis. [3] [4] [5] [6] LXRs affect cell biology well beyond cholesterol metabolism. For instance, the antiatherosclerotic properties of LXR agonists also involve anti-inflammatory actions. 7 Furthermore, LXR agonists can restrain the proliferation of several cell types by affecting cell cycle control and prosurvival pathways. [8] [9] [10] [11] [12] [13] [14] The precise mechanisms linking these complex effects to cholesterol homeostasis are largely unknown. One possibility is that LXR-dependent cholesterol mobilization may affect the structure and dynamics of specific membrane and vesicular compartments. Indeed, T0901317 has been shown to reduce the size and associated signaling of lipid rafts, cholesterolenriched domains of the plasma membrane constituting fundamental signaling hubs for multiple transduction pathways. 13, 15 Administration of LXR agonists can impair multicellular processes that involve angiogenesis, such as liver regeneration and tumor growth. 9, 13, 16 We and others have reported that endothelial cells express functional LXRs, with LXRβ representing the most important LXR isoform in this cell type. [17] [18] [19] Endothelial cells are particularly sensitive to cholesterol levels, given their wide membrane surface and richness in lipid rafts/caveolae. In line with this view, impairment of cholesterol homeostasis with itraconazole or cyclodextrin has been previously shown to affect vascular endothelial growth factor receptor-2 (VEGFR2) signaling in endothelial cells. 20, 21 Taken together, these findings imply that the tissue actions of LXR agonists may also involve so far unappreciated antiangiogenic effects.
Herein, we show that the pharmacological activation of endothelial LXRs is antiangiogenic as a result of synergistic reductions in cell migration, tubulogenesis, and proliferation. The antiangiogenic effects of LXR agonists involve endothelial cholesterol depletion and impaired VEGFR2 compartmentation and signaling. These findings highlight the potential for LXR-targeted therapeutic interventions in conditions of pathological angiogenesis.
Methods
A full description of experimental methods is provided in the onlineonly Data Supplement.
Gene Expression Analysis
RNA was extracted using affinity columns (Qiagen, Hilden, Germany) or TRIzol (Invitrogen, Carlsbad, CA). Microarray gene expression profiling was performed with HG-U133 Plus 2.0 microarrays (Affymetrix). 19 For quantitative reverse transcription real-time polymerase chain reaction, mRNA levels were analyzed using the 2 −ΔΔCt relative quantification system with 18S rRNA as the housekeeping gene. Gene silencing was performed with short hairpin RNA (shRNA) Mission RNA interference vectors (Sigma, St. Louis, MO) against LXRβ (Target Set NM_007121) or scramble shRNA.
Cell Cholesterol
Lipids were extracted using chloroform:isopropanol: tergitol-type NP-40 (7:11:0.1). After homogenization and spinning, the organic phase was dried and suspended in a reaction mix containing cholesterol oxidase and a colorimetric probe (Biovision, Milpitas, CA). Absorbance at 570 nm was finally measured in a microplate reader.
Immunofluorescence
Human umbilical vein endothelial cells (HUVECs) were fixed with 4% paraformaldehye, blocked, and incubated with anti-caveolin-1 (Santa Cruz, Santa Cruz, CA) and anti-VEGFR2 (R&D systems, Minneapolis, MN) antibodies, followed by incubation with secondary antibodies (Molecular Probes, Invitrogen). Nuclei were counterstained with DAPI (Molecular Probes, Invitrogen). Images were captured with a Leica AF6000 workstation equipped with a total internal reflection fluorescence module and analyzed with ImageJ software. Tumor sections were incubated with anti-ABCA1 (Novus Biological, Littleton, CO) or anti-CD31 (BD Biosciences Franklin Lakes, NJ) antibodies. Images were acquired by using a Leica TCS SP2 AOBS confocal microscope and analyzed with Leica Confocal Software.
Cell Fractionation
For fractionation, cell lysates were adjusted to 45% sucrose by the addition of 90% sucrose and placed into ultracentrifugation tubes. A 5% to 35% sucrose discontinuous gradient was formed above, and samples were centrifuged at 246×10 3 g for 16 hours at 4°C in a SW-55Ti rotor (Beckman, Brea, CA). Ten fractions were collected from the top of each gradient.
Migration and Tubulogenesis Assays
HUVEC migration was assayed in a Boyden's chamber with a gelatin-coated polycarbonate membrane. The lower compartment of the chamber was filled with endothelial basal medium-2 (Lonza, Basel, Switzerland) containing vascular endothelial growth factor-A (VEGF-A; 10 ng/mL). HUVECs were serum starved overnight in the presence of the indicated compounds and then added to the upper compartment of the chamber. After 5 hours of incubation, the membrane was fixed and stained for microscopic analysis.
Tubulogenesis assays were performed in solidified basement membrane matrix (Matrigel; BD Biosciences). After incubation with the indicated compounds, HUVECs were seeded and overlaid with EGM-2 medium (Lonza) containing the indicated compounds. After 8 hours, tubular structures were microscopically examined and photographed (Leica, Wetzlar, Germany) for subsequent processing.
Cell Viability and Cell Cycle
Cell viability was determined using the tetrazole assay (Roche, Penzberg, Germany). For apoptosis, annexin-positive HUVECs were detected using the Annexin V-PE apoptosis kit (Merck, Whitehouse Station, NJ). HUVEC proliferation rate and cell cycle were evaluated using the Click-iT EdU flow cytometry assay kit (Invitrogen) and propidium iodide staining, as described.
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Animal Studies
Wild-type mice were 8-to 12-week-old female C57BL/6. The generation of LXRα −/− /LXRβ −/− mice has been previously described. 23, 24 Animal procedures were approved by the local ethics committee.
Aortic Ring Angiogenic Assay
Thoracic aortas were removed from 8-to 12-week-old mice and incubated in serum-free medium with treatment compounds. 25 Rings were transferred to Matrigel-coated culture dishes and covered with endothelial growth medium containing the indicated compounds. Tubular structures were examined with an inverted-phase contrast microscope and photographed (Leica) for subsequent processing.
In Vivo Neoangiogenesis
In vivo neoangiogenesis was performed using a modified directed in vivo angiogenesis assay (Trevigen, Gaithersburg, MD). On day 14, mice were euthanized, and angioreactors were dissected. The vascularized basement membrane extract of each angioreactor was recovered and digested using CellSperse solution (Trevigen). Vesselderived cells were pelleted, suspended in PBS, and counted by fluorescence-activated cell sorter analysis.
Tumor Grafts
For Lewis lung carcinoma (LLC-1) grafts, 10 6 cells were injected subcutaneously into the back of 8-to 12-week-old female C57BL/6 mice. After 1 week, mice were randomized into a treatment group (T0901317 in 0.5% carboxymethyl cellulose-0.25% Tween 20, 20 mg/kg IP QD) and a control group (same amount of vehicle). Tumor growth was checked daily by caliper measurement. Mice were euthanized after 1 week of treatment.
Data Analysis
Quantification of tubular structures was performed with WinRhizo Pro software (Regent Instruments, Quebec City, QC, Canada). 
Results
LXR Activation Reduces HUVEC Cholesterol
Human endothelial cells express functional LXRs. In line with transcriptional data, T0901317 caused a robust protein induction of cholesterol transporters ABCA1 and ABCG1 ( Figure 1F ), which mediate cholesterol efflux and reverse cholesterol transport. 27, 28 Instead, cholesteryl ester transfer protein and sterol regulatory element binding transcription factor 1c protein levels were only marginally affected by T0901317 in HUVECs. Accordingly, T0901317 reduced HUVEC cholesterol content dose-dependently ( Figure 1G ).
LXR Activation Inhibits Endothelial Migration and Tubulogenesis
Modifications in endothelial cholesterol balance and trafficking have been shown to affect key biological processes. 21, 29, 30 To assess the impact of LXR activation on endothelial angiogenesis, we first examined the effect of different LXR agonists on VEGF-A-induced migration of HUVECs. LXR agonists GW3965 and T0901317 reduced migration dose-dependently compared with vehicle ( Figure  2A ). To rule out off-target effects of LXR-activating compounds, HUVEC migration was also evaluated in the background of LXR silencing. Although T0901317 reduced the migration of HUVECs infected with scramble shRNA, T0901317 did not affect the migration of LXRβ-silenced HUVECs ( Figure 2B ). HUVECs treated with GW3965 or T0901317 also showed a significant impairment in Matrigel tubulogenesis. GW3965 and T0901317 reduced the average tubule length by 47±14% and 55±10% (P<0.05) ( Figure  2C ) and the fork number by 63±9% and 68±11% (P<0.05) ( Figure Figure 2D ). Taken together, these findings suggested that inhibition of endothelial migration and morphogenesis by LXR agonists is mediated by LXR-specific effects on cell cholesterol homeostasis.
LXR Activation Inhibits Endothelial Proliferation Without Affecting Apoptosis
Besides motility, angiogenesis involves endothelial proliferation. As LXR agonists have been shown to reduce cell cycle progression in non-endothelial cells, [8] [9] [10] [11] 14 we assessed the effect of LXR agonists on HUVEC proliferation. GW3965 and T0901317 reduced HUVEC proliferation dosedependently ( Figure 3A) . A similar effect was also produced by natural LXR agonist 22-hydroxycholesterol ( Figure IIIC in the online-only Data Supplement). T0901317 reduced the protein levels of cyclins A and D1 and increased the protein levels of cyclin-dependent kinase inhibitor p27/Kip-1 ( Figure 3B ), indicating that LXR activation specifically perturbs cell cycle progression, as previously reported in other cell types. 14, 31, 32 However, T0901317 did not cause apoptosis ( Figure 3C ). Incubation of HUVECs with T0901317 specifically restrained the G 1 -S cell cycle transition, as assessed by propidium iodide staining ( Figure 3D) , and reduced the DNA incorporation of a thymidine analog ( Figure 3E ). The effect of T0901317 on G 1 -S transition and DNA synthesis was relieved by coincubation of HUVECs with exogenous cell-soluble cholesterol ( Figure 3D and 3E), thus indicating that LXR activation impairs endothelial cell cycle and proliferation by affecting cell cholesterol homeostasis.
LXR Activation Reduces Signaling of VEGFR2
The observed effects of LXR agonists in endothelial cells suggested the involvement of LXR in the angiogenic signaling. As previously reported in macrophages, T0901317 upregulated the mRNA expression of VEGF-A also in HUVECs ( Figure IVA in the online-only Data Supplement). 33 However, the protein levels of VEGF-A were unchanged by T0901317 in HUVECs ( Figure IVB in the online-only Data Supplement). The mRNA and protein expressions of VEGFR2, the pivotal VEGF receptor controlling angiogenesis, 34 were not affected by T0901317 ( Figure IVC 
LXR Activation Reduces Compartmentation of VEGFR2 in Lipid Rafts/Caveolae
Cholesterol depletion by T0901317 has been associated with a decrease in lipid raft size and signaling. 13 We thus tested the hypothesis that T0901317 may affect VEGFR2 signaling by impairing its compartmentation in lipid rafts/caveolae. We analyzed the cell surface distribution of caveolar rafts, visualized by caveolin-1 staining, and of VEGFR2, by total internal reflection fluorescence microscopy. Treatment of HUVECs with T0901317 reduced the caveolin-1-positive area by 53±8% (P<0.05) ( Figure 4D and 4E) , indicating a depletion in endothelial lipid rafts/caveolae. Furthermore, the amount of VEGFR2 localized in caveolar structures was reduced by 54±7% (P<0.05) ( Figure 4D and 4F) . The effect of T0901317 on caveolin-1 and VEGFR2 compartmentation was blunted by the addition of exogenous cell-soluble cholesterol ( Figure 4E and 4F) . Membrane fractionation experiments confirmed that T0901317 displaced VEGFR2 from the buoyant flotillin-2-positive and caveolin-1-positive fractions (1-3), representing endothelial lipid rafts/caveolae. Instead, the amount of VEGFR2 in the heavier, binding immunoglobulin protein-positive fractions, representing the endoplasmic reticulum, was not affected (Figure 4G and 4H) . Coincubation of HUVECs with exogenous cell-soluble cholesterol attenuated the T0901317-dependent depletion of VEGFR2 in lipid rafts/caveolae ( Figure 4I ), indicating that LXR activation modifies VEGFR2 membrane compartmentation by affecting cell cholesterol homeostasis.
LXR Activation Inhibits Endothelial Sprouting and In Vivo Neoangiogenesis
The impact of LXR agonists on angiogenesis was next assayed ex vivo and in vivo. Incubation of mouse aortic rings with GW3965 or T0901317 reduced ex vivo endothelial sprouting by 89±2% and 73±10%, respectively, compared with vehicle (P<0.05). However, endothelial sprouting was unchanged by T0901317 when aortic rings were coincubated with cholesterol, indicating that LXR activation impairs endothelial sprouting through cholesterol depletion ( Figure 5A ). T0901317 reduced endothelial sprouting when applied to aortic rings obtained from wild-type mice but not to rings obtained from mice deficient for LXRs (LXRα −/− /LXRβ −/− ) ( Figure 5B ), thus confirming that the antiangiogenic effect of T0901317 is LXR-specific. In vivo neoangiogenesis was next assessed through the subcutaneous implantation in mice of angioreactors containing VEGF-A and fibroblast growth factor-enriched extracellular matrix. Addition of T0901317 to the extracellular matrix critically reduced neoangiogenesis by 86±7% compared with vehicle (P<0.05) ( Figure 5C ), as assessed by red blood cell content in the angioreactors 2 weeks after implantation. Taken together, these data indicated that LXR agonists can inhibit angiogenesis in mouse tissues.
LXR Activation Inhibits Tumor Angiogenesis
Neoangiogenesis is strictly required for tumor growth. To highlight the effect of LXR activation on cancer angiogenesis, we used LLC-1 tumor grafts. Contrary to HUVECs, LLC-1 cells did not regulate the protein levels of cholesterol transporters ABCA1 and ABCG1 upon treatment with T0901317 ( Figure 6A) . Also, the levels of low-density lipoprotein receptor (LDLR) were unchanged by T0901317 in LLC-1 cells. Of note, T0901317 did not modify the proliferation ( Figure  VA tumor growth by 62±20% on day 7 compared with vehicle (P<0.05) ( Figure 6B ). Body weight remained similar in treated and control animals (data not shown). Administration of T0901317 upregulated ABCA1 mRNA within the tumor mass ( Figure VE in the online-only Data Supplement). In particular, T0901317 significantly increased the protein expression of ABCA1 selectively within tumor endothelial cells ( Figure  6C ). Of note, T0901317 treatment reduced the endothelial density of LLC-1 tumors by 50±3% compared with vehicle (P<0.01), as assessed by CD31 immunostaining of tumor sections ( Figure 6D ). Taken together, these findings indicated that pharmacological targeting of LXRs can significantly reduce tumor angiogenesis.
Discussion
We provide evidence that LXR activation can restrain angiogenesis. The antiangiogenic effects of LXR agonists are strictly connected to their impact on endothelial cholesterol homeostasis, because coincubation of HUVECs or aortic rings with exogenous cholesterol largely neutralized the actions of LXR agonists on endothelial tubulogenesis, sprouting, and proliferation. These results are in line with previous reports that drugs leading to cholesterol deprivation or impaired cholesterol trafficking, such as β-cyclodextrin, itraconazole, or high-dose statins, can negatively affect angiogenesis. 29, 30, 35 In endothelial cells, T0901317 lowered cell cholesterol by regulating the expression of multiple targets. In particular, LXR activation increased the protein levels of cholesterol transporters ABCA1 and ABCG1, which promote cholesterol output toward apolipoprotein A-containing lipoproteins, as well as transendothelial high-density lipoprotein traffic. 28, 36 T0901317 also increased the mRNA expression of inducible degrader of the low-density lipoprotein receptor, which targets LDLR to ubiquitin-mediated The lipid raft compartment is represented in the lighter fractions (1-3), whereas the endoplasmic reticulum peaks in the heavier fractions (7) (8) (9) (10) . Representative blots of 3 experiments.
degradation. 37 As the expression of LDLR is negligible in HUVECs, the effect of LXRs on endothelial cholesterol homeostasis is, therefore, essentially mediated by ABCA1 and ABCG1, at least in vitro. We previously reported that incubation of endothelial cells with natural LXR agonist 22(R)-hydroxycholesterol downregulates the expression of several genes controlling cholesterol biosynthesis, such as 3-hydroxy-3-methylglutaryl-coenzyme A reductase, mevalonate kinase, and squalene epoxidase. 19 Hence, natural oxysterol LXR ligands may further impact on endothelial cholesterol homeostasis through synergic effects on cholesterol synthesis and traffic. Nonetheless, we cannot exclude that antiagiogenic effects of LXRs may also relate to so far unappreciated perturbations of the nonsterol branch of the mevalonate pathway. For instance, LXR agonists may modify the synthesis of isoprenoids and affect protein prenylation, which is required for proper compartmentation and function of key proteins involved in angiogenesis (eg, small GTPases).
Cholesterol is essential to maintain a normal structure and function of cellular membranes. Furthermore, cholesterolrich microdomains of the plasma membrane called lipid rafts/caveolae function as preferential sites for membrane receptor clustering and signaling. 15 LXR activation has been previously shown to reduce lipid raft size and restrain lipid raft-associated signaling in a cancer cell line. 13 We now provide evidence that in endothelial cells, treatment with LXR agonist T0901317 specifically impairs biological signals stemming from lipid raft/caveolar domains that are critical for angiogenesis. In particular, LXR activation (1) impaired VEGFR2 phosphorylation and downstream signaling to PLCγ, and (2) blunted the compartmentation of VEGFR2 in lipid rafts/caveolae. Both effects appear to be mediated by the LXR-dependent perturbation of cholesterol homeostasis.
These findings are in line with previous data showing that changes in endothelial cholesterol affect VEGFR2 signaling, most likely as a result of complex interactions of the receptor and its signaling platform within lipid rafts/caveolae. 20, 21 Nonetheless, the molecular circuitry linking cholesterol balance to angiogenesis is only beginning to emerge. In our study, LXR activation significantly reduced caveolin-rich regions of the plasma membrane. As knockout of caveolin-1 inhibits angiogenesis by impairing VEGFR2 compartmentation and by causing a detrimental deregulation of endothelial NO synthase, LXR activation may restrain angiogenesis by altering the physiological conditions of caveolin-1 expression and internalization, and possibly endothelial NO synthase activity. 38, 39 Furthermore, as lipid rafts/caveolae are membrane microdomains harboring multiple signaling platforms, we cannot exclude that the effects of LXR activation may extend to other relevant receptors and pathways, such as those of fibroblast growth factor or transforming growth factor-β.
We provide evidence that the antiangiogenic effects of LXR activation can be therapeutically meaningful, because T0901317 reduced both the vascularization and tumor growth of LLC-1 grafts. Of note, the anti-cancer properties of T0901317 were detectable only in vivo, because this drug did not modify the proliferation and apoptosis of LLC-1 cells in vitro. The resistance of LLC-1 cells to LXR activation is in line with previous observations that LXR agonists can impair cell cycle progression and favor apoptosis (eg, by increasing the expression of p27/Kip-1) only in certain cancer cell lines, whereas others are resistant to LXR activation. 9, 12, 13, 40 It has been suggested that the sensitivity to LXR agonists may relate to the cell-specific effects of LXRs on cholesterol homoeostasis. 31 Our findings support this hypothesis, because in LLC-1 cells T0901317 did not modify the expression of both cholesterol-handling proteins (ABCA1, ABCG1, and LDLR) and cell cycle regulator p27/Kip-1.
Taken together, the present findings picture a scenario where LXR agonists can limit cancer growth in vivo by exerting substantial antiangiogenic effects. Nonetheless, it can be foreseen that in certain cancer types, the angiostatic properties of LXR-activating compounds may synergize with direct antiproliferative and pro-apoptotic actions of LXRs on tumor cells. As the systemic administration of LXR-activating drugs is presently limited by side effects, such as liver steatosis and increased LDL-cholesterol, these drugs may find earlier applications as locally delivered therapies. 
